J&J files in Europe for first-line Imbruvica use in CLL; First-to-market races mean small R&D leads can pay off big;

> Johnson & Johnson's ($JNJ) Janssen unit submitted an application for expanded European approval of its blood cancer drug Imbruvica, as a therapy for previously untreated patients with chronic lymphocytic leukemia. Release

> These days, it's common to see several drugs racing for a first-in-class approval, which means that small accelerations in R&D can yield big payoffs, a Tufts University study found. Report

> Johnson & Johnson and GlaxoSmithKline's ($GSK) ViiV Healthcare joint venture touted data from Phase II studies of two long-acting injectable versions of now-daily HIV pills. Release | Report

And Finally ... Mylan ($MYL) won U.S. antitrust approval to buy Perrigo ($PRGO), provided it sells off rights to several generic products. Release

Suggested Articles

Moving into the Final Four of the #FierceMadness drug name tournament, contenders from both Big Pharma and smaller companies remain evenly in play.

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.